Clinical Leadership Sunstone is a leading provider of psychedelic-assisted therapy in medical settings with extensive experience in clinical trial execution and a path toward clinical delivery post-approval, signaling readiness for partnerships on trial design, data collection, and regulatory submission support.

Cancer Care Model Their patient-centric, oncology-informed operational model supports complex, multi-faceted care at scale, presenting opportunities to partner on integrated care pathways, risk management, and scalable program design for cancer-related mental health and trauma therapies.

Expansion News Recent and ongoing study expansions (MDMA‑assisted Dyad Study growth; IIT funded by Maryland and grants) indicate active program scaling and government/grant-backed collaboration potential for joint research initiatives and funded pilots.

Strategic Partnerships Past collaborations with academic and research institutions (University of Vermont) demonstrate openness to partnerships for feasibility studies, observational research, and evidence generation that could be expanded with industry sponsors, CROs, and academic alliances.

Funding & Growth Revenue and funding levels (1–10M revenue; 8.5M funding) suggest a growth window for strategic alliances, co-development of trial infrastructure, technology platforms, and scalable clinic design services tailored to psychedelic therapies.